Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125525291 | 12552529 | 1 | I | 20160707 | 20160713 | 20160713 | PER | US-PFIZER INC-2016337238 | PFIZER | 48.00 | YR | M | Y | 79.90000 | KG | 20160713 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125525291 | 12552529 | 1 | PS | ZOSYN | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | UNK | N | 50684 | INJECTION | |||||||||
| 125525291 | 12552529 | 2 | SS | MEROPENEM. | MEROPENEM | 1 | UNK | N | 90940 | ||||||||||
| 125525291 | 12552529 | 3 | SS | LEVAQUIN | LEVOFLOXACIN | 1 | UNK | N | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125525291 | 12552529 | 1 | Pseudomonas infection |
| 125525291 | 12552529 | 2 | Pseudomonas infection |
| 125525291 | 12552529 | 3 | Pseudomonas infection |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125525291 | 12552529 | Drug resistance | |
| 125525291 | 12552529 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125525291 | 12552529 | 1 | 20160506 | 20160517 | 0 | |
| 125525291 | 12552529 | 2 | 20160517 | 20160531 | 0 | |
| 125525291 | 12552529 | 3 | 20160507 | 20160511 | 0 |